he price of CAR-T therapy often dominates the conversation. Yet for patients and families, the true value of these therapies cannot be measured by cost alone.

By the time a patient becomes eligible for CAR-T, they have often endured multiple lines of treatment, several hospitalizations, unsuccessful therapies, and the emotional uncertainty that accompanies a life-threatening diagnosis. The healthcare system has invested substantial resources along the way as well. Viewed in that context, the question shifts from “How much does this therapy cost?” to something far more consequential:

Are healthcare systems measuring value in the right way?

That question framed a multidisciplinary discussion during the 2026 DIA Global Annual Meeting, where a panel of patient advocates, clinicians, and reimbursement experts explored how CAR-T therapies are challenging long-held assumptions about value, access, and sustainability. Although the conversation centered on oncology, the themes that emerged reach far beyond cancer. They point toward a future in which healthcare systems must evolve as rapidly as the science they are intended to support.

CAR-T: A Stress Test for Modern Healthcare

Few innovations illustrate this challenge more clearly than CAR-T therapy.

Unlike many traditional treatments that are delivered repeatedly over months or years, CAR-T may require a significant upfront investment while offering the potential for durable remission, and, for some patients, years without additional therapy. Yet the reimbursement and health technology assessment (HTA) systems used to evaluate these treatments were largely designed around chronic disease management, recurring treatment cycles, and annual budget planning.

The US experience also illustrates that these systems can adapt. Changes to Medicare payment policy, including the creation of a dedicated payment category for CAR-T, helped address some of the challenges associated with the substantial costs of delivering these therapies. Yet an important question remains: how can reimbursement and assessment approaches capture benefits that may extend well beyond a single payment year or budget cycle?

Rather than creating new problems, CAR-T has exposed existing ones. It has become a real-world stress test for healthcare systems, revealing a growing disconnect between what modern medicine can accomplish and how healthcare systems evaluate, reimburse, and deliver innovation.

Importantly, this challenge is unlikely to remain confined to oncology, the first therapeutic area where a CAR-T cell therapy was approved and commercialized. Cell and gene therapies are rapidly expanding into additional disease areas, raising broader questions about whether today’s policies are prepared for tomorrow’s medicine.

The Therapy Is Changing Too

The challenge is not static. CAR-T itself is evolving.

The panel pointed to advances that could make cell therapies faster, more scalable, and potentially less costly. Innovations in manufacturing are already shortening the time required to produce some therapies, while emerging approaches—including in vivo engineering of T cells and the development of more readily available or potentially “off-the-shelf” approaches—could further change how these therapies are delivered in the future.

At the same time, researchers are working to overcome some of the biological limitations that have made CAR-T more challenging to apply to solid tumors, including the hostile tumor microenvironment that can limit T-cell function.

These developments could fundamentally change the economics, logistics, and delivery of cell therapy. They also underscore the urgency of ensuring that healthcare systems, reimbursement models, and infrastructure evolve alongside the science.

Looking Beyond the Price Tag

Throughout the discussion, panelists repeatedly returned to one central idea: value cannot be defined by upfront cost alone.

For patients, value may mean seeing children grow up, returning to work, or living years free from repeated hospitalizations. For healthcare systems, it may mean avoiding years of chronic treatment, disease progression, and repeated medical interventions. At the societal level, it extends even further: to caregiver burden, workforce participation, and the long-term sustainability of healthcare.

The patient perspective brought this reality into sharp focus. Often, by the time patients receive CAR-T, they have already undergone months (or years) of intensive treatment, with repeated hospitalizations, mounting medical costs, and the uncertainty of not knowing whether the next treatment will work. Focusing exclusively on the price of a single therapy risks overlooking the cumulative clinical, emotional, and financial costs that came before it.

The discussion also broadened the definition of value beyond what happens after a therapy is administered. Value begins with getting the diagnosis right and identifying the most appropriate treatment for each patient. More precise diagnosis and treatment selection could help reduce exposure to ineffective therapies, avoid unnecessary toxicity, and prevent costs associated with treatment pathways that ultimately fail.

The discussion also challenged whether current reimbursement models are equipped to capture the full value of transformative therapies. Most payment decisions continue to be evaluated within annual budget cycles, even though the benefits of these therapies may extend over decades.

One comparison illustrated this shift in thinking particularly well. Vaccination programs, such as those preventing HPV-related cancers, have long been accepted because of the substantial health and economic benefits they generate over time, even though those returns are realized many years after the initial investment. The panelists suggested that transformative therapies may require a similar perspective: one that recognizes lifetime value rather than focusing primarily on immediate expenditure.

Seen through this lens, CAR-T is prompting the healthcare system to ask a much larger question:

How should value be measured when a single intervention has the potential to replace years of treatment?

Access Is the Next Innovation Challenge

Scientific breakthroughs alone do not improve outcomes if patients cannot benefit from them.

The panel emphasized that access challenges extend well beyond reimbursement. Geographic location, referral pathways, manufacturing capacity, provider expertise, and healthcare infrastructure all influence whether eligible patients receive treatment and when.

For many patients, receiving CAR-T still requires traveling long distances to specialized treatment centers. The discussion highlighted families who had to raise money simply to travel to treatment, as well as patients whose disease progressed while they waited a long time for access. For some, obtaining a visa can become part of the treatment journey. In these situations, the distance between regulatory approval and actual treatment can be measured in weeks, months, or years, or, for some patients, in whether treatment arrives in time for them. Delays in referral or manufacturing can have further profound consequences, particularly for rapidly progressing diseases. But as one panelist put it, for patients, these barriers are rarely experienced as abstract policy problems.

As transformative therapies become more common, success will increasingly depend on strengthening partnerships between specialized centers and community providers, expanding clinical expertise, and ensuring that advanced therapies reach patients wherever they live.

The patient perspective served as an important reminder that these barriers are never simply logistical or financial. They shape treatment decisions, create uncertainty for families, and ultimately determine whether scientific breakthroughs become real-world improvements in care.

Innovation only changes lives when patients can access it.

Precision Medicine Starts Earlier

The discussion also reflected a broader evolution in precision medicine.

Rather than asking which treatment should be used after multiple therapies have failed, the focus is increasingly shifting toward identifying the right intervention earlier in the disease journey. Earlier molecular testing and improved diagnostics can help avoid ineffective therapies, reduce unnecessary toxicity, and connect patients with the most appropriate treatment sooner.

For one panelist, this question was also deeply personal. By the time he received CAR-T, he had already undergone multiple treatment regimens and an autologous stem-cell transplant. His experience raised an important question: could earlier identification of the most appropriate treatment have changed his treatment journey and potentially reduced some of the clinical and financial burden associated with interventions that ultimately did not provide a lasting benefit?

The implications extend beyond any individual treatment journey. More precise diagnosis and treatment selection can help healthcare systems avoid the costs of ineffective interventions while ensuring that patients have an opportunity to receive the therapies most likely to benefit them at the right point in their disease journey.

This evolution represents more than an incremental improvement in cancer care. It signals a broader transition: from reacting to disease toward anticipating it, using biological insights to intervene earlier, more precisely, and with greater potential for long-term benefit.

From Cancer Care to Healthy Aging

Perhaps the most forward-looking portion of the discussion explored what today’s oncology breakthroughs may mean for the future of medicine.

Advances in understanding the biology of aging suggest that many chronic diseases, including cancer, Alzheimer’s disease, cardiovascular disease, and diabetes, share common biological mechanisms. Researchers are increasingly exploring whether therapies that target these underlying pathways could delay or prevent multiple diseases rather than treating each one individually after it develops.

Within this broader context, CAR-T also illustrates how technologies originally developed for cancer may eventually find applications beyond oncology. Early research is exploring whether engineered cellular therapies, including CAR-T approaches directed at senescent cells, could eventually have applications beyond cancer. These approaches remain investigational, but they illustrate how technologies developed for one disease area may ultimately be applied to broader biological mechanisms of disease and aging.

The panel emphasized that the future is not simply about extending lifespan; it’s about extending healthspan: enabling people to remain healthier, more independent, and free from disease for longer.

That observation may ultimately extend far beyond oncology.

If healthcare systems struggle today to measure the long-term value of curative cancer therapies, the same challenge will arise as medicine increasingly focuses on preventing disease, slowing biological aging, and improving healthspan. The longer the benefits of an intervention take to materialize, the more difficult they may be to capture within traditional reimbursement and valuation frameworks. This underscores why discussions about transformative therapies increasingly intersect with broader questions of societal investment, and whether healthcare systems are equipped to recognize value that unfolds over decades. Even modest gains in healthy years of life have the potential to generate profound benefits for patients, healthcare systems, and society.

Redefining Value for Tomorrow’s Medicine

The discussion ultimately returned to a simple but profound idea: healthcare systems must evolve as rapidly as the science intended to support them.

The panel’s proposed solutions were as multidimensional as the challenge itself. Bringing transformative therapies closer to patients will require stronger community infrastructure and partnerships beyond specialized centers. Advancing precision medicine can help identify the right treatment for the right patient earlier in the disease journey. At the same time, continued innovation in manufacturing could make cell therapies faster, more scalable, and potentially less costly, while advances in regulatory science could help reduce unnecessary development burdens without compromising patient safety. Public investment in advanced therapies and infrastructure will also be important to sustaining this progress.

Together, these changes point to a broader need for the healthcare ecosystem to evolve in concert. Payment and reimbursement models must also adapt to recognize benefits that may extend well beyond the initial treatment and across a patient’s lifetime.

CAR-T may have been the catalyst for this conversation, but it is unlikely to be the last therapy to challenge existing assumptions.

The future of medicine is increasingly defined by interventions that promise not merely to manage disease but to alter its trajectory—or even prevent it altogether.

As that future comes into sharper focus, the question is no longer whether innovation is advancing quickly enough.

It is whether our definition of value can evolve just as rapidly.